The aim of the present work was to develop a chromatographic technique coupled with mass spectrometry for the measurement of lamotrigine in plasma. Lamotrigine and guanabenz (internal standard) were measured by selected reaction monitoring. The method was validated and applied in a bioequivalence trial on 26 female volunteers. Lamotrigine chewable tablets (100 mg) were administered and monitored for up to 96 h. Results: The method was linear between 0.05 and 5.0 µg/ml, with acceptable stability, accuracy and precision. Mean maximum plasma concentration was 1.37 µg/ml and was reached at 1.6 h postdose. Elimination half-life was 32.7 h. Conclusion: Lamotrigine tablets were bioequivalent. Ultra-performance liquid chromatography with tandem mass spectrometry represents a powerful tool in terms of sensitivity, specificity and high-throughput ana lysis.
ReseaRch aRticle
Lamotrigine (LMT; 3,5-diamino-6-[2,3-dichlorophenyl]-1,2,4-triazine; Figure 1 ) is an antiepileptic drug that has been used for over 20 years in the clinical treatment of several types of tonic-clonic seizures in adults, and in the Lennox-Gastaut syndrome in children. Recently, LMT has also been utilized in the treatment of bipolar disorders and as a mood stabilizer. The molecular mechanism of LMT effects might lie in inhibition of synaptic release of glutamate by regulating the recovery of inactivated sodium channels [1] .
Lamotrigine is a lipophilic weak base (pKa = 5.7) that is totally absorbed from the gastrointestinal tract and metabolized predominantly by glucuronidation. It exhibits an elimination half-life between 24 and 35 h, with a plasma peak time at approximately 2 h. It has been reported that following a single oral dose of 200 mg of LMT, plasma concentrations up to 2.5 µg/ml were reached [2] .
Depending on the purpose of the technique (therapeutic drug monitoring in children or in pregnant women, pharmacokinetics or drug-drug interactions), several methods have been developed for LMT quantification in bio logical fluids. One of the first techniques reported using 50 µl, is based on highperformance liquid chromatography (HPLC) with ultra violet (UV) detection employing liquid-liquid extraction [3] ; however, these authors failed to mention the selectivity of the technique regarding LMT metabolites.
Recently, several methods based on HPLC-UV were published, with the inconvenient lack of selectivity associated with this detection type. In addition, some of these methods of LMT extraction involving direct precipitation of plasma proteins have long running times due to the necessity to separate other molecules in the same sample [4, 5] , or implies the use of solid-phase extraction [6] [7] [8] [9] . Recently, an automated, rapid and sensitive HPLC-UV method has been reported using column-switching for online sample cleaning [10] . At present, HPLC coupled with mass spectrometry (MS) has been recognized as the gold standard for measurement of drugs and their metabolites in a very sensitive and specific manner. Initial attempts to measure LMT by HPLC-MS utilized very small amounts of plasma, either by direct precipitation [11] or by solid-phase extraction [12] ; nonetheless, these maintained long running times and failed to increase sensitivity due to LMT monitoring in 'single ion monitoring' mode. The coupling of ultra-performance liquid chromatography with tandem MS (UPLC-MS/MS) dramatically increased the bioanalytical possibilities by creating a rapid, sensitive and specific analytical tool.
Thus, the aim of the present work was to develop a method for plasma quantification of LMT by means of the employment of small amounts of sample based on UPLC-MS/MS and in a non-time-consuming fashion, and its further application in a bioequivalence trial.
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Experimental
Reagents Lamotrigine (purity 100.35%, R A Chem Pharma Ltd., Hyderabad, India) and Guanabenz acetate (GBZ) (purity >99%, Sigma-Aldrich Chemical Co., St Louis, MO, USA) (Figure 1) were kindly provided by Landsteiner Scientific Laboratories (Mexico City, Mexico). HPLCgrade acetonitrile and methanol, ammonium acetate (purity: 97%) and acetic acid (purity: 99.7%) were purchased from JT Baker (Xalostoc, Mexico). Milli-Q ultra-pure water (Billerica, MA, USA) was used for solutions and mobile-phase preparations, while citrated human plasma was obtained from the blood bank at our hospital.
Standards & controls
Master stock solutions of LMT (200 and 10 µg/ml in methanol) and GBZ (200 µg/ml in 70% methanol, internal standard of the technique) were prepared monthly and maintained at 4°C and protected from light. Working solutions of GBZ (1 µg/ml in 70% methanol) and tenfold concentrated working solutions of LMT (0.5, 1.5, 5, 10, 20, 25, 30, 40 and 50 µg/ml in 70% methanol) were prepared weekly and maintained at the same conditions. Drug-free plasma was spiked with the corresponding LMT working solution to obtain a calibration curve at concentrations of 0.05, 0.5, 1, 2, 3 and 5 µg/ml. In the same way, quality control points were prepared at low, medium, and high concentration levels (0.15, 2.5, and 4 µg/ml). Separately, 100 ng/ml solutions of LMT and GBZ in 70% methanol were employed for mass spectrometer tuning and during ion suppression assays.
Instrumentation
The analytical platform consisted of a Waters Acquity UPLC (Milford, MA, USA) coupled with a Waters Micromass Quattro Micro tandem mass spectrometer (Manchester, UK) employing MassLynx 4.1™ software. The analytical column was an Acquity BEH RP18 (1.7 µm particle size, 100 mm × 2.1 mm internal diameter), which was maintained at 45°C. Mobile phase consisted of a mixture of acetonitrile and ammonium acetate 10 mM, pH 4.0 (50:50 v/v) that was pumped at a 300 µl/min flow rate. The autosampler was kept at 10°C, and a volume of 10 µl per sample was injected into the system. The mass spectrometer was employed in positive electro-spray ionization mode (ESI + ); LMT and GBZ were monitored through selected reaction monitoring using 
Sample preparation
For calibration standards, quality control points and unknown samples, 100 µl of these were pipetted into 1.5-ml microcentrifuge tubes. Samples were added with 20 µl of working solution of GBZ and acidified with 20 µl of acetic acid. Tubes were briefly vortex-mixed, and then plasma proteins were precipitated with 400 µl of cold acetonitrile (4°C). Samples were vortexmixed for 30 s at high speed and centrifuged at 13,000 × g at 4°C for 5 min. Subsequently, 300 µl of clear supernatants were transferred into 96-well 'V-bottom' polypropylene plates (Corning, Inc., NY, USA) and placed in the autosampler for further injection into the system. Quantification was achieved by using the six-point calibration curve based on LMT/GBZ peak area ratios versus LMT concentrations in a 1/x-weighted linear model.
Assay validation
Ion suppression was evaluated by injecting processed drug-free plasma samples of six different batches onto the UPLC and simultaneous infusion of a 100 ng/ml working solution, first of LMT and later GBZ; disturbances at baseline were monitored throughout the entire running time. Batches that did not show interference were Development of an UPLC-MS/MS micromethod for quantification of lamotrigine | ReseaRch aRticle pooled for analytical validation. Besides, lower limit of quantification was prepared in lipemic or hemolized plasma; lower limit of quantification were also spiked with aspirin, caffeine, chlorphenamine, acetaminophen or butylhyoscine. Independent responses of LMT and GBZ were compared with limit of quantification prepared in normal pooled plasma. The analytical method was validated according to criteria established in Mexican Regulatory Guidelines [13, 101] . Quality control points were utilized to determine absolute recovery and within-and between-day precision and accuracy. Limit of quantification, stability (biological matrix at -70°C, bench-top at room temperature, freeze-thaw cycles and processed samples inside the autosampler) and selectivity were also evaluated.
Clinical trial
In total, 26 healthy female volunteers participated in the bioequivalence study and fulfilled the following inclusion criteria: aged between 18 and 45 years; nonsmokers or having quit smoking 72 h prior to study initiation; body mass index between 20 and 27; normal clinical history; normal values in laboratory tests (hematology, blood biochemistry, hepatic function and urine ana lysis) and negative results for pregnancy, AIDS and type-B hepatitis tests. Signed informed consent (according to the Declaration of Helsinki) was obtained from each volunteer, and the study protocol was reviewed and approved by the Ethics Board of the Hospital General de México.
All subjects received a single oral dose of 100 mg LMT chewable tablets of the following two formulations: the test formulation (Landsteiner Scientific, S.A. de C.V., Mexico City, Mexico) and the reference formulation (Lacmital™, GlaxoSmithKline, SA de CV, Mexico City, Mexico). The bioequivalence trial comprised of a classically designed twoperiod, two-sequence, double-blind, crossover randomized trial with a 14-day washout period. Blood samples of approximately 4 ml were taken through a cannula in vacuum tubes with the addition of sodium heparin at 0 h (prior to LMT administration) and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 24, 48, 72 and 96 h after dosing. Plasma was separated by centrifugation at 3500 rpm at 4°C during 10 min, transferred into labeled cryovials and stored at -70°C until LMT ana lysis.
Statistical ana lysis
All statistical procedures during validation were performed using WINNONLIN™ version 3.1 software (Pharsight Co., Mountain View, CA, USA). Pharmacokinetic parameters were calculated by programming plasma data, a single extra-vascular dose, and a noncompartmental model also utilizing WINNONLIN. Elimination half-life (t ½ ), area under the curve to last measurable concentration (AUC 0-t ), and AUC extrapolated to infinity (AUC 0-∞ ) were software outputs. Maximum observed plasmatic concentration (C max ) and time of C max (T max ) were experimentally obtained by observation of the kinetic profiles of each volunteer.
For the bioequivalence study, analysis of variance for a standard 2 × 2 crossover design was used to evaluate fixed effects such as period, sequence, formulation and carryover. AUC 0-t , AUC 0-∞ and C max considered as primary variables. Decimal logarithm values of these parameters were taken into consideration to construct a classic confidence interval at 90% with a significance level (a) of 0.05. Moreover, interval hypothesis based on two one-sided procedures (Schuirmann's test) was evaluated with a significance level (a) of 0.05; ReseaRch aRticle | Marcelín-Jiménez, P Angeles, Mendoza-Morales et al.
both data analyses were conducted according to US FDA recommendations for establishing bioequivalence [14] .
Results & discussion
To our knowledge, GBZ had never been used as an internal standard of LMT in MS techniques, but indeed, has been previously used in HPLC-UV due to their related spectrophotometric properties [3] . Thus, and considering their similarities in terms of solubility and structure, it was decided to adopt this with good results. Spectrograms of both LMT and GBZ are shown in Chromatography Figure 3 shows chromatograms of pooled blank plasma, lower limit of quantification and the C max of one volunteer. LMT and GBZ eluted at 0.85 and 0.9 min, respectively, with a total run time of 1.5 min. As can be observed, baseline for each channel is quite stable and peaks are welldefined, although a direct precipitation technique was employed. To achieve a very clean sample, we noted that full protein removal was performed when cold acetonitrile (4°C) was used in a 4:1 proportion to plasma, when vortex mixing was performed for no more than 30 s (more time disrupts clogged proteins), and when samples were allowed to remain at 4°C for 5 min prior to centrifugation.
One of the main goals of UPLC lies in the very short running times, which are translated into high-throughput techniques with low solvent consumption.
Assay validation Linearity & limit of quantification
The calibration curve was linear in the 0.05-5 µg/ml concentration range in a first-order model (area ratio = -0.156 + 0.047 [concentration]; r 2 = 0.996).
The signal-to-noise ratio was 1500:1 (coefficient of variation [CV] = 3.5%) for the low limit of quantification, which permitted us to quantify LMT up to 96 h postdose in the clinical trial, which was sufficient time to define pharmacokinetic profiles. Our method is at least ten-times more sensitive in terms of the LMT-injection amount compared with the previously reported HPLC-MS technique [11] .
Recovery, accuracy & precision
Recoveries for LMT and GBZ were estimated by comparing peak areas in extracted spiked human drug-free plasma (control points) with those in standard solutions, and were: 0.151 µg/ml (100.7%; CV: 2.3%), 2.48 µg/ml (99.19%; CV: 2.7%) and 3.9 µg/ml (97.4%; CV: 2.6%) for the low, medium and high levels, respectively; which should be expected in a direct precipitation technique. Assay within-and between-day accuracy and precision values are presented in Table 2 .
Stability assays
Lamotrigine proved stable in biological samples for at least two 24-h freeze-thaw cycles (final mean recovery of 104.8%; CV: 2.83%) and for at least 5 h on the benchtop at 25°C and 31% relative humidity (101.6%; CV: 2.06%): this was more than sufficient because the precipitation technique is not time consuming.
Moreover, processed samples were stable for at least 12 h in the autosampler (100.2%; CV: 3.81%), which made it possible to analyze all samples of both periods of five volunteers per day, including calibration, quality control and washing points (~240 injections).
Lamotrigine in plasma was stable for at least 70 days at -70°C (100.3%; CV: 2.36%). To our knowledge, this is the first fully validated UPLC-MS/MS method for LMT.
Finally, it is known from previous reference [11] that during the precipitation technique there is no conversion of lamotrigine-2-N-glucuronide (main metabolite of LMT) to free LMT during sample preparation.
Ion suppression & selectivity
There were no endogenous compounds that might interfere with either LMT or GBZ ionization in the plasma samples tested for the assay, nor did lipemia exhibit ion suppression.
However, hemolysis suppresses the LMT signal by 25%, which must be considered during quantification of this type of sample. It is future science group Development of an UPLC-MS/MS micromethod for quantification of lamotrigine | ReseaRch aRticle important to note that we obtained full hemolysis. Heparinized blood (in vacuum tubes) was placed for 10 min in an ultrasonic bath; then the sample was centrifugated and 100% hemolized plasma was collected.
Selectivity results demonstrated that there were no interfering peaks from any of the following drugs: aspirin, caffeine, chlorphenamine and heparin. However, acetaminophen and butylhyoscine demonstrated interference with LMT quantification. Acetaminophen increased the area of GBZ by 10%, while butylhyoscine suppressed the signal of both molecules by 90%. This may be explained by ionization and/or phasetransference competition among all molecules under certain chromatographic conditions [15, 16] .
The clinical trial
All volunteers finished both phases of clinical trial (no drop-outs were registered) and formed a homogeneous population in terms of age (25.5 ± 4.9 years), weight (58.4 ± 7.4 kg), Transitions for both LMT and GBZ are shown in independent channels.
ES+: Positive electrospray ionization mode; LMT: Lamotrigine; GBZ: Guanabenz; MRM: Multiple reaction monitoring.
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Development of an UPLC-MS/MS micromethod for quantification of lamotrigine | ReseaRch aRticle and body mass index (23.25 ± 1.9 kg/m 2 ). One important aspect of the protocol was to assure that formulations were completely chewed and swallowed with 250 ml of tap water to homogenize the LMT absorptive phase. No adverse effects were reported during the trial.
Pharmacokinetics & bioequivalence
Concentration-time value profiles of the 26 volunteers for the two formulations are shown in Figure 4 , indicating that plasma drug concentrations of both formulations were quite similar, and that final samples were sufficient for calculating greater than 80% of AUC 0-a . Attempting to monitor more than 96 h in order to describe a higher percentage in AUC 0-a , increases the risk of 'drop-outs' in this type of trial. All calculated pharmacokinetic parameters of both LMT tablet brands are summarized in Table 3 . Reference product data were compared with previously reported results in a study in which 200 mg of LMT were administered (twice the amount employed in present work) [4] . Within this dosage range, LMT exhibited linear pharmacokinetics because twice the amount of C max was also reported. The main difference was observed in T max : while we reported 1.64 h in the present work, the cited study reported approximately 2.4 h (46% later); this difference could be explained by the sampling schedule. T max is an average of times in which C max are observed; in previous work, authors sampled C max at 1, 2 and 4 h, while in the present work we conducted sampling at 1, 1.5, 2 and 2.5 h, obtaining a more precise estimation of this parameter.
Concerning the bioequivalence results, as can be observed, 90% confidence interval for all compared parameters (ratios of C max , AUC 0-t and AUC 0-a ) were contained within the 80-125% interval. Moreover, the Schuirmann's test for all analyzed parameters exhibited no significant differences with a statistical power of greater than 99% in each tested parameter. Thus, it can be concluded that both formulations are bioequivalent. This might be supposed a priori, because LMT was swallowed after being completely chewed and taken with water, implying that there was no gastric-disruptive tablet phase. Thus, both formulations were administered completely disintegrated.
Conclusions
Use of UPLC at pressures between 4000 and 7000 psi and flows between 200 and 400 µl allows the occurrence of three important phenomena when coupled with mass spectrometers; first, small chromatographic flows are easily evaporated by the spectrometer, and ReseaRch aRticle | Marcelín-Jiménez, P Angeles, Mendoza-Morales et al.
second, when the mobile phase passes from ultra pressures to atmospheric pressure at high temperature, it expands itself, facilitating formation of the gas phase. These two phenomena optimize the transference of ions from liquid to gas phase on entrance into the spectrometer. Finally, such flows avoid peak broadening, which together with the selectivity of tandem mass spectrometry, render this coupling more sensitive than traditional HPLC-MS/MS. Regarding the pharmacokinetic results of chewable soluble LMT tablets, it may be suggested that dissolution profile can be a suitable test in these types of formulations for bioequivalence purposes.
Future perspective
The amazing advances in mass spectrometry and in separative techniques (such as UPLC and new column supports) will allow us to increase the sensitivity of quantitative bioanalytical method ology dramatically, with less time spent on extractive procedures and with use of a minimum of biological samples.
One interesting application of this trend could lie in the drug monitoring of children, not only for LMT but also for any drug whose monitoring is critical, with less invasive techniques and processing micro-samples. Finally, at a future opportunity, our group will investigate the pharmacokinetics of LMT in male volunteers in order to establish gender-related differences in the Mexican population. 
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Executive summary
Assay validation
A linear calibration curve between 0.05 and 5 µg/ml is optimal for describing the pharmacokinetic profile after a 100 mg oral dose of lamotrigine (LMT). Direct precipitation provides clean samples with acceptable ionic interferences, which permits LMT quantification by tandem mass spectrometry with the accuracy and precision required in a regulatory framework.
Pharmacokinetics & bioequivalence
Based on results previously reported, and compared with the obtained in present study, LMT exhibits a linear pharmacokinetic. The 26 volunteers comprise of an adequate sample size for reaching statistical power over 80% in LMT bioequivalence trials due to low population variability. 96 h is sufficient time for blood sampling that describes over 80% of area under the curve extrapolated to infinity. Dissolution test should be adopted as a suitable assay for chewable-soluble LMT tablets.
